Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET)
Articolo
Data di Pubblicazione:
2018
Citazione:
Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET) / V. De Gennaro Colonna, C. Pavanello, F. Rusconi, A. Sartore-Bianchi, S. Siena, S. Castelnuovo, C.R. Sirtori, G. Mombelli. - In: JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS. - ISSN 1365-2710. - 43:1(2018), pp. 114-116. [10.1111/jcpt.12588]
Abstract:
WHAT IS KNOWN AND OBJECTIVE:
Hypertriglyceridaemia (HTG) is a potentially serious side effect of everolimus therapy. We here report a case of severe HTG in an everolimus-treated patient and provide recommendations for its management.
CASE SUMMARY:
The patient was a 70-year-old woman, being treated with everolimus for a pancreatic neuroendocrine tumour (pNET). She developed severe HTG to a maximum of 969 mg/dL after 22 months of therapy. Treatment with fenofibrate rapidly normalized triglyceride (TG) levels.
WHAT IS NEW AND CONCLUSION:
Severe HTG may occur in everolimus-treated patients. Prescription of the appropriate therapy can allow patients to continue this medication.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
everolimus; fenofibrate; hypertriglyceridaemia; mammalian target of rapamycin inhibitors
Elenco autori:
V. De Gennaro Colonna, C. Pavanello, F. Rusconi, A. Sartore-Bianchi, S. Siena, S. Castelnuovo, C.R. Sirtori, G. Mombelli
Link alla scheda completa: